MedDataX Logo

The Role of Cxcr4Hi neutrOPhils in InflueNza

NCT ID: NCT06254313

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Most of severe influenza patients suffer from acute lung injury due to a dysregulated immune response. Neutrophils are involved in both host resistance and disease tolerance. Thanks to advances in technologies, the vast variety in neutrophils subpopulations has been revealed. In particular, the subpopulation of CXCR4-expressing neutrophils has been suggested to be involved in the rupture of disease tolerance in lung infections. Nevertheless, these data are from murine models and remain to be confirmed in humans. Moreover, the underlying mechanisms remain unknown as well as the place of primum movens, i.e. vascular or alveolar compartment. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors. Percentage of BAL CXCR4-expressing neutrophils will also be compared. To this aim, blood sampling and BAL within the 24 hours and at day 3 after admission to ICU, neutrophils isolation, immunostaining and flow cytometry acquisition will be performed within the 24 hours and at day 3 after admission to ICU. Mortality rate will be collected at Day 28 and Day 90.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Acute Respiratory Distress Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

neutrophils CXCR4 host resistance disease tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Influenza-related ARDS group

Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.

Additional tubes and LBA

Intervention Type OTHER

4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Bacterial-related ARDS group

A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.

Additional tubes and LBA

Intervention Type OTHER

4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Extra-pulmonary (digestive inflammation) ARDS group

Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging).

Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.

Additional tubes and LBA

Intervention Type OTHER

4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Additional tubes and LBA

4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 yo or above.
* Acute respiratory distress syndrome as defined by the Berlin classification.
* Invasive mechanical ventilation for less than 24 hours.
* Cause of ARDS:

* Influenza infection proven by polymerase chain reaction OR
* Bacterial infection (tracheal aspirate with more than 105 CFU/mL and BAL with more than 104 CFU/mL.
* Pancreatitis according to the 2013 Working Group IAP/APA Acute Pancreatitis Guidelines.
* Peritonitis according to the 2018 SFAR guidelines.
* Health insurance.
* Written informed consent from legal relative or representative.

Exclusion Criteria

* Neutropenia (\< 500/mm3)
* Neutrophils qualitative defect.
* Patient included in an interventional research assessing an immunomodulatory or antiviral drug.
* Acquired ImmunoDeficiency Syndrome.
* Contraindication to BAL:

* Severe bronshospasm.
* Out-of-control shock.
* Intracranial high pressure.
* Refractory hypoxemia (PaO2/FiO2 \< 60 mmHg).
* Legal restriction: prisoners, pregnancy, legal protection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bordeaux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edouard LHOMME, Dr

Role: STUDY_CHAIR

Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique du CHU de Bordeaux

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Pellegrin

Bordeaux, , France

Site Status RECRUITING

Hopital Haut-Lévêque

Pessac, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Renaud PREVEL, Dr

Role: CONTACT

Phone: 5 57 87 26 26

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Renaud PREVEL, Dr

Role: primary

Antoine DEWITTE, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUBX 2023/41

Identifier Type: -

Identifier Source: org_study_id